false
--12-31
0001721484
0001721484
2024-03-19
2024-03-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 19, 2024
Longeveron Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-40060 |
|
47-2174146 |
|
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1951
NW 7th Avenue, Suite 520,
Miami, Florida
33136
(Address of principal executive offices)
Registrant’s telephone number, including
area code: (305) 909-0840
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Class A Common Stock, $0.001 par value per share |
|
LGVN |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.03 Amendments to Articles of Incorporation
or Bylaws; Change in Fiscal Year.
On
February 21, 2024, the stockholders of Longeveron Inc. (the “Company”) approved a proposal at a special meeting of stockholders
(the “Special Meeting”) to amend the Company’s Certificate of Incorporation (as amended, the “Certificate of Incorporation”),
to effect a reverse stock split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par
value $0.001 per share (collectively, the Company’s “Common Stock”), at a ratio between one-for-five (1:5) and one-for-fifteen
(1:15), without reducing the authorized number of shares of Common Stock. On March 19, 2024, the Company’s Board of Directors approved
a final reverse stock split ratio of one-for-ten (1:10). Following such approval, the Company filed a certificate of amendment to the
Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the reverse
stock split, with an effective time of 11:59 p.m., Eastern Time on March 26, 2024.
As
a result of the reverse stock split, every ten shares of the Company’s Common Stock, whether issued and outstanding or held by the
Company as treasury stock, will automatically be combined and converted (without any further act) into one share of fully paid and nonassessable
share of Common Stock. No fractional shares will be issued in connection with the reverse stock split. Each fractional share of Common
Stock that would otherwise be issued as a result of the reverse stock split will be rounded up to the nearest whole share of Common Stock.
The
new CUSIP number for the Company’s Class A common stock following the reverse stock split is 54303L
203. The Company’s Class A common stock will open for trading under the new CUSIP number on the Nasdaq Capital Market on
March 27, 2024 on a split-adjusted basis under the current ticker symbol “LGVN.”
The
description of the Amendment set forth above does not purport to be complete and is qualified in its entirety by the full text of the
Amendment, a copy of which is attached hereto as Exhibit 3.1(a) and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
On
March 19, 2024, the Company issued a press release announcing the one-for-ten (1:10) reverse stock split. A copy of the press release
is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In
accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, which
is incorporated into this Item 7.01, is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for the purposes
of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except as shall be expressly
set forth by reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
LONGEVERON INC. |
| |
|
| Date: March 19, 2024 |
/s/
Lisa A. Locklear |
| |
Name: |
Lisa A. Locklear |
| |
Title: |
Chief Financial Officer |
2
Exhibit
3.1(a)
CERTIFICATE
OF AMENDMENT
TO
THE
CERTIFICATE
OF INCORPORATION
OF
LONGEVERON
INC.
Longeveron
Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the
State of Delaware (the “DGCL”), does hereby certify:
1. |
Pursuant
to Section 242 of the DGCL, this Certificate of Amendment to the Certificate of Incorporation (this “Certificate of Amendment”)
amends the provisions of the Certificate of Incorporation of the Corporation (the “Charter”). |
| |
|
| 2. |
This
Certificate of Amendment has been approved and duly adopted by the Corporation’s Board of Directors and stockholders in accordance
with the provisions of Section 242 of the DGCL. |
| |
|
| 3. |
Upon
this Certificate of Amendment becoming effective, the Charter is hereby amended as follows: |
ARTICLE
FOURTH of the Charter is hereby amended by adding the following new paragraph C at the end of such article:
“C.
REVERSE STOCK SPLIT
Effective
at 11:59 p.m., Eastern Time, on the day this Certificate of Amendment to the Certificate of Incorporation of the Corporation is filed
and declared effective pursuant to the DGCL (the “2024 Split Effective Time”), every ten (10) shares of Class A Common Stock
issued and outstanding or held by the Corporation as treasury shares as of the 2024 Split Effective Time shall automatically, and without
action on the part of the stockholders, be combined, reclassified and changed into one (1) validly issued, fully paid and non-assessable
share of Class A Common Stock and every ten (10) shares of Class B Common Stock issued and outstanding or held by the Corporation as
treasury shares as of the 2024 Split Effective Time shall automatically, and without action on the part of the stockholders, be combined,
reclassified and changed into one (1) validly issued, fully paid and non-assessable share of Class B Common Stock, in all instances without
effecting a change to the par value per share of common stock, and subject to the treatment of fractional interests as described below
(the “2024 Reverse Split”). Notwithstanding the immediately preceding sentence, no fractional shares will be issued
in connection with the combination effected by the preceding sentence. The Board of Directors shall make provision for the issuance of
that number of fractions of shares of Class A Common Stock or Class B Common Stock such that any fractional share of a holder otherwise
resulting from the 2024 Reverse Split shall be rounded up to the next whole number of shares of Class A Common Stock or Class B Common
Stock, as applicable. As of the 2024 Split Effective Time and thereafter, a certificate(s) representing shares of Class A Common Stock
or Class B Common Stock prior to the 2024 Reverse Split is deemed to represent the number of post-2024 Reverse Split shares into which
the pre-2024 Reverse Split shares were reclassified and combined. The 2024 Reverse Split shall also apply to any outstanding securities
or rights convertible into, or exchangeable or exercisable for, Class A Common Stock or Class B Common Stock, as applicable, of the Corporation
and all references to such Class A Common Stock or Class B Common Stock in agreements, arrangements, documents and plans relating thereto
or any option or right to purchase or acquire shares of Class A Common Stock or Class B Common Stock shall be deemed to be references
to the Class A Common Stock or Class B Common Stock or options or rights to purchase or acquire shares of Class A Common Stock or Class
B Common Stock, as the case may be, after giving effect to the 2024 Reverse Split.”
| 4. | This
Certificate of Amendment shall become effective at 11:59 p.m., Eastern Time, on March 26,
2024. |
*
_ * _ * _ *
IN
WITNESS WHEREOF, the undersigned authorized officer of the Corporation has executed this Certificate of Amendment to the Amended
and Restated Certificate of Incorporation as of March 19, 2024.
|
LONGEVERON
INC. |
| |
|
|
| |
By: |
/s/ Wa’el Hashad |
| |
Name: |
Wa’el Hashad |
| |
Title: |
Chief Executive Officer |
Exhibit 99.1
Longeveron Announces 1-for-10 Reverse Stock
Split
MIAMI, FL, March 19, 2024 (GLOBE NEWSWIRE) –
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing
regenerative medicines for unmet medical needs, announced today that the Company’s Board of Directors has approved a 1-for-10 reverse
split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (the
“common stock”) (the “Reverse Split”). The Reverse Split was previously approved by the Company’s stockholders
at a special meeting held on February 21, 2024 The Reverse Split will legally take effect at 11:59 p.m. Eastern Time, on March 26, 2024.
The Company’s Class A common stock will open for trading under a new CUSIP number 54303L 203
on The Nasdaq Capital Market on March 27, 2024, on a split-adjusted basis under the current ticker symbol “LGVN.” The Reverse
Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance
with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The Reverse Split will automatically convert every
ten current shares of the Company’s common stock, whether issued and outstanding or held by the Company as treasury stock, into
one share of fully paid and nonassessable common stock. No fractional shares will be issued in connection with the Reverse Split. Stockholders
of record who would otherwise be entitled to receive a fractional share of the Company’s common stock following the Reverse Split
will be entitled to rounding up of the fractional share to the nearest whole number.
The Reverse Split will reduce the aggregate number
of shares of outstanding Class A common stock from approximately 10,295,426 shares to approximately 1,029,543 shares, and the number of
shares of outstanding Class B common stock from approximately 14,839,993 shares to approximately 1,484,000 shares (based on outstanding
shares as of March 18, 2024). The total authorized number of shares will remain unchanged. The terms of all outstanding warrants currently
exercisable for shares of Class A common stock, and all equity awards granted under the Company’s equity plans, including the per
share exercise price of options and the number of shares issuable under such options, will be proportionally adjusted to maintain their
economic value, subject to adjustments for any fractional shares as described above. In addition, the total number of shares of shares
of common stock that may be the subject of future grants under the Company’s equity plans, as well as any plan limits on the size
of such grants will be adjusted and proportionally decreased as a result of the Reverse Split.
Stockholders holding their shares electronically
in book-entry form are not required to take any action to receive post-Reverse Split shares. Stockholders owning shares through a bank,
broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers’ particular
processes, and will not be required to take any action in connection with the Reverse Split. For those stockholders holding physical stock
certificates, the Company’s transfer agent, Colonial Stock Transfer Company, Inc., will send instructions for exchanging those certificates
for shares held electronically in book-entry form or for new certificates, in either case representing the post-Reverse Split number of
shares, including the impact of any rounding to the nearest whole number of shares in lieu of fractional shares, if applicable.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company
developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™
an allogeneic Mesenchymal Stem Cell (MSC) formulation sourced from the bone marrow of young, healthy adult donors. Lomecel-B™ has
multiple potential mechanisms of action that promote tissue repair and healing with broad potential applications across a spectrum of
disease areas. The underlying mechanism(s) of action that may lead to the tissue repair programs
include the stimulation of new blood vessel formation, modulation of the immune system, reduction in tissue fibrosis, and the stimulation
of endogenous cells to divide and increase the numbers of certain specialized cells in the body. Longeveron is currently pursuing
three pipeline indications: Hypoplastic Left Heart Syndrome, Alzheimer’s disease, and Aging-related Frailty. Additional information
about the Company is available at www.longeveron.com.
Forward-Looking Statements
Certain statements in this press release that
are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance
and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated
by the statements made herein. Further, certain forward-looking statements are based on assumptions as to future events that may not prove
to be accurate, including the Company’s expectations regarding the effect of the Reverse Split and its continued listing on Nasdaq.
Forward-looking statements are generally identifiable
by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,”
“will,” “should,” “plan,” “intend,” “on condition,” “target,”
“see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative
thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that
could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include,
but are not limited to, our limited operating history and lack of products approved for commercial sale; adverse global conditions, including
macroeconomic uncertainty; inability to raise additional capital necessary to continue as a going concern; a history of losses and may
not be able to achieve profitability going forward; no FDA-approved allogenic, cell-based therapies for Aging-related Frailty, AD, or
other aging-related conditions, nor HLHS or other cardiac-related indications; ethical and other concerns surrounding the use of stem
cell therapy or human tissue; the use of our product candidates or future products in individuals may expose us to product liability claims,
and we may not be able to obtain adequate product liability insurance; if our trade secret and patent position does not adequately protect
our product candidates and their uses, others could compete against us more directly, which could harm our business and have a material
adverse effect on our business, financial condition, and results of operations; if certain license agreements are terminated, our ability
to continue clinical trials and commercially market products could be adversely affected; inability to protect the confidentiality of
our proprietary information, trade secrets, and know-how; third-party claims of intellectual property infringement may prevent or delay
our product development efforts; intellectual property rights do not necessarily address all potential threats to our competitive advantage;
inability to successfully develop and commercialize our product candidates and obtain the necessary regulatory approvals; we cannot market
and sell our product candidates in the U.S. or in other countries if we fail to obtain the necessary regulatory approvals; final marketing
approval of our product candidates by the FDA or other regulatory authorities for commercial use may be delayed, limited, or denied, any
of which could adversely affect our ability to generate operating revenues; we may not be able to secure and maintain research institutions
to conduct our clinical trials; ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our
business and results of operations; if we receive regulatory approval of Lomecel-B™ or any of our other product candidates, we will
be subject to ongoing regulatory requirements and continued regulatory review, which may result in significant additional expense; being
subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our therapeutic candidates;
reliance on third parties to conduct certain aspects of our preclinical studies and clinical trials; interim, “topline” and
preliminary data from our clinical trials that we announce or publish from time to time may change as more data become available and are
subject to audit and verification procedures that could result in material changes in the final data; the volatility of price of our Class
A common stock; we could lose our listing on the Nasdaq Capital Market if our current share price continues to decrease; provisions in
our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our company or
changes in our management and, therefore, depress the market price of our Class A common stock; we have never commercialized a product
candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or
together with suitable collaborators; and in order to successfully implement our plans and strategies, we will need to grow our organization,
and we may experience difficulties in managing this growth. Further information relating to factors that may impact the Company’s
results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including
Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission
on February 27, 2024, as amended on Form 10-K/A on March 11, 2024 and its Quarterly Reports on Form 10-Q. The forward-looking statements
contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation,
other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events,
or otherwise.
Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com
v3.24.1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
| Name: |
dei_CurrentFiscalYearEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:gMonthDayItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Longeveron (NASDAQ:LGVNR)
過去 株価チャート
から 5 2024 まで 6 2024
Longeveron (NASDAQ:LGVNR)
過去 株価チャート
から 6 2023 まで 6 2024
